secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2024-03-06T23:59:59+00:00
Accession:  0000950170-24-026868
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan Q4 net loss $19.6M; all 8 TSC-100/101 patients relapse-free
-----------------------------------------------------------------

- Q4 revenue $7.2M (up from $3.1M YoY); full-year revenue $21.0M. R&D expenses $22.4M Q4, $88.2M full year.
- Cash $192M as of Dec 31, 2023; cash runway into 2026.
- Phase 1 heme data: 8/8 treatment-arm patients relapse-free; one high-risk MDS patient reached 1 year post-TSC-101.
- FDA cleared INDs for TSC-201-B0702 (MAGE-C2) and TSC-204-A0101 (MAGE-A1); solid tumor trial enrolling.
- Appointed Jason Amello as CFO, Justin McCue as CTO; promoted several executives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000095017024026868/0000950170-24-026868-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000095017024026868/tcrx-20240306.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-026868

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer